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The leukocyte function-associated molecule 1 (LFA-1) plays a key 
role in cell adhesion among leukocytes and between leukocytes 
and other cell types12. Although two ligands3’4 ofLFA-1 have 
been identified, namely the intercellular adhesion molecules 1 
(ICAM-1) and 2 (ICAM-2), the exact mechanism by which IF A-1 
binds to and detaches from its ligand(s) has remained obscure. 
Based on novel findings5>6 Carl Figdor, Yvette van Kooyk and 
Gerrit Keizer now present a model of LFA- 7 -mediated lympho­
cyte adhesion, showing that LFA-1 -dependent cell adhesion is a 
dynamic process in which ligand-binding affinity is regulated by 
intramolecular changes in LFA-1 This process is controlled by 
other lymphocyte surface structures, notably CD2 and CD3.
The LFA-1 family of adhesion receptors consists of three 
structurally related glycoproteins, LFA-1 # CR3 and 
p150,95, which comprise the CD11 —CD 18 group of ad­
hesion molecules. They have similar architecture and are 
composed of two non-covalently linked polypeptides: a 
unique a subunit (CD11a-c) and a common (3 subunit 
(CD 18). Cloning of the CD11 genes revealed the presence 
of three potential cation-binding sites on each of the 
individual a chains7-9.
Based on structural homology, the LFA-1 group of 
adhesion molecules belongs to the integrin family of 
adhesion receptors10-11. However, in contrast to other 
integrins, the LFA-1 family of antigens is exclusively ex­
pressed on leukocytes. LFA-1-mediated adhesion is ac­
complished by binding to I CAM-1, ICAM-2 orto other, as 
yet unidentified, ligands3-4. In contrast to the restricted 
tissue distribution of LFA-1, ICAM-1 is widely distributed, 
and its expression can be induced by a variety of inflam­
matory cytokines12.
LFA-1—ligand interaction
Much has been learned about the conditions required 
for LFA-1-ligand interaction. LFA-1-mediated cell ad­
hesion is a temperature- and energy-dependent process 
that requires an intact cytoskeleton and the presence of 
divalent cations, notably Mg2+ (Refs 6,13,14).
Apart from these conditions that must be fulfilled to 
enable LFA-1-mediated cell-cell interactions, several ob­
servations indicate that LFA-1 -dependent adhesion iscon-
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trolled by other cellular processes. Resting leukocytes do 
not adhere spontaneously, but several stimuli can induce 
LFA-1-mediated cell-cell interactions. Phorbol myristate 
acetate (PMA) strongly induces LFA-1 -dependent cell ad- 
hesionMJ5. In addition, monoclonal antibodies directed 
against the cell surface molecules CD2 and CD3 have now 
been shown to stimulate cell aggregation5-6.
One possible conclusion from these observations is that 
surface molecules, like CD2 and CD3, can activate LFA-1 
through intracellular signalling pathways, and that acti­
vation of LFA-1 leads to enhanced ligand binding6. This 
hypothesis implies the existence of at least two different 
forms of LFA-1 - an inactive and an active form. A strong 
argument in favour of the existence of these two states of 
LFA-1 is that if only one form of LFA-1 existed, spon­
taneous aggregation of peripheral blood leukocytes 
would cause clogging of blood vessels. This notion is 
supported by the fact that freshly isolated leukocytes do 
not tend to aggregate to each other, although they 
express significant levels of LFA-1 and ICAM-1. Similarly, 
cloned cytotoxic T lymphocytes (CTL) and natural killer 
(NK) cells, which express extremely high levels of LFA-1 
and ICAM-1, do not aggregate spontaneously5'14. How­
ever rapid aggregation of CTL can be observed upon 
stimulation with antigen, PMA, or through CD2 or CD3. 
This cell clustering is LFA-1-dependent, since it is abro­
gated by anti-LFA-1 antibodies. Furthermore, the induced 
cell adhesion cannot be attributed to a short-term aug­
mentation of surface expression of LFA-1 and ICAM-1 
(Refs 5,6,13). These observations, therefore, provide 
further evidence for the existence of an inactive and an 
active form of LFA-1.
Activation of LFA-1
What causes LFA-1 to transform from an inactive into 
an active state? An anti-LFA-1 antibody, termed NKI-L16, 
was recently described16 that, in contrast to other anti- 
LFA-1 antibodies, stimulates cell adhesion rather than 
inhibiting LFA-1-dependent cell-cell interactions. NKI- 
L16-induced cell aggregation does not involve intracellu­
lar signalling, but appears to aiterthe conformation of the 
LFA-1 molecule such that its affinity for ligand binding is
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Fig. 1. Model for regulation of LFA-1-mediated cett adhesion. Binding of antigen to TCR-CD3 
complex stimulates phosphohpase C (PLC) that catalyses the hydrolysis of phosphatidyl inositol 
bis-phosphate (PIPJ producing inositol trisphosphate (IP3) which mobilizes intracellular calcium 
and diacylglyceroi (DAG). Subsequent phosphorylation of the p chain of LFA-7 causes a 
conformational change leading to high-affimty ligand binding. LFA-Independent cell adhesion is 
downregula ted by phosphorylation ofCD3 resulting in modulation of the TCR-CD3 complex, As 
a consequence, PKC levels fall and phosphatases dephosphorylate LFA-1$, reversing it into its 
inactive state, thus facilitating de-adhesion PMA and NKI-U 6 activate LFA-1 by direct activation 
of PKC or by binding to LFA-1 respectively.
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greatly enhanced (Y. van Kooyk, P. Weder, F. Hogervorst, 
A.J. Verhoeven, A.A. le Velde, J. Borst, G.D. Keizer and 
C.G. Figdor, submitted). In time course studies measuring 
cell aggregation induced by NKI-L16 or by PMA, strikingly 
similar kinetics were observed16, suggesting that aggre­
gation induced by PMA may also result from a confor­
mational change in LFA-1. PMA is a potent activator of 
protein kinase C (PKC), which, when activated, can phos- 
phorylate the cytoplasmic tails of a variety of surface 
proteins17. Indeed increased phosphorylation of the LFA-1 
(3 chain has been reported after stimulation with PMA, 
while the.« chain of the molecule seems to be con- 
stitutively phosphorylated18 21. It has previously been pro­
posed that phosphorylation is directly related to activation 
of LFA-1 (G.D. Keizer, PhD Thesis, University of Amster­
dam, 1987), Phosphorylation of the (3 chain may induce a 
conformational change in the LFA-1 molecule, thus in­
creasing its affinity for ligands (Fig. 1)22.
Although PMA directly activates PKC, activation 
through CD2 or CD3 is thought to stimulate inositol 
phospholipid metabolism thereby giving rise to activation 
of PKC23-24. CD2 and CD3 may thus provide the physio­
logical signals required to activate LFA-1. Support for the 
proposal that LFA-1 can become activated through CD2 
and CD3 triggering has been obtained by measuring 
binding avidities in cell adhesion experiments to ICAM-1 
(Ref. 6) and by measuring cell-cell adhesion5. Inter­
estingly, CD3 triggering leads to transient LFA-1 acti­
vation5'6 (reduced to background levels after 30 min)y 
while stimulation via CD2 is long-lived5, which indicates 
that different signalling routes may be involved, it is 
known that triggering of CD2 or CD3 involves PKC acti­
vation, but it has not yet been shown that triggering of
278
these molecules indeed leads to phosphorylation of the 
LFA-13 chain.
Role of LFA-1 in target-cell lysis by cytotoxic T lymphocytes
CTL-target-celi interactions have been extensively 
studied and provide, arguably, the best model to demon­
strate the mode of action of LFA-1. Figure 2 shows the 
various phases through which a cytolytic reaction pro­
gresses. It is suggested that, when CTL encounter a target 
cell, initial cell-cell contact is established via LFA-1 — 
ICAM-1 interaction25 2S. At this stage cell binding is non­
specific and of low affinity since it does not involve 
antigen recognition. Nevertheless, target cell binding is 
strong enough to facilitate antigen recognition by the 
T-cell receptor (TCR)-CD3 complex. Without antigen rec­
ognition, the CTL detach from the target cell. If, however, 
antigen is recognized, CD3 transmits a signal which ul­
timately leads to activation of LFA-1 via phosphorylation 
of the (3 chain. Activated LFA-1 then mediates high- 
affinity binding between CTL and target cell, thereby 
strengthening the adhesion between them29. This facili­
tates the formation of intercellular clefts30, enabling ef­
ficient delivery of cytotoxic molecules to the target cell. 
Furthermore, activated LFA-1 may interact with cytoskel- 
etal elements, thereby directing the migration of cytotoxic 
granules. Modulation of the TCR-CD3 complex from the 
cell surface31 is thought to abrogate PKC-mediated fuel­
ling of protein phosphorylation, thus acting as a negative 
feedback signal reverting LFA-1 to its inactive state (Fig. 1) 
and providing CTL with a mechanism which may lead to 
detachment from target cells (Fig. 2).
Three different forms of LFA-1 on the cell surface
So far we have proposed that there are two forms of 
LFA-1: an inactive and an active form. We now propose a 
third form of LFA-1 which lacks the epitope recognized by 
the mAb NKI-L16 (Fig. 3). Resting peripheral blood lym­
phocytes (PBL) express LFA-1, but express extremely low 
levels of the NKI-L16 epitope in comparison with CTL16, It 
has been observed that the speed with which cells aggre­
gate upon stimulation directly correlates with expression 
of the NKI-L16 epitope (Y. van Kooyk, P. Weder, F. 
Hogervorst, A.J. Verhoeven, A.A. le Velde, J. Borst, G.D. 
Keizer and C.G. Figdor, submitted), suggesting that ex­
posure of the NKI-L16 epitope is a prerequisite for LFA-1 - 
dependent adhesion. This is supported by the finding that 
in vitro culture (3-6 h) of resting PBL with interleukin 2 
(IL-2) increases NKI-L16 expression and correlates with 
their capacity to aggregate. This is not due to an increased 
number of LFA-1 molecules expressed, since it is not 
accompanied by a concomitant rise in expression of LFA-1 
epitopes other than NKI-L16. These observations show 
that the majority of LFA-1 molecules expressed by resting 
PBL lack the NKI-L16 epitope or that all LFA-1 molecules 
only partially expose the epitope (inactive LFA-1; Fig. 3(1)). 
At the moment it is not possible to distinguish between 
these possibilities.
Further evidence in favour of an NK1-L16-negative form 
of LFA-1 comes from the observation that the NKI-L16 
epitope completely disappears when CTL, expressing high 
levels of NKI-L16, are treated with ethylenediamine- 
tetraacetate (EDTA) or ethyleneglycolbis(aminoethylether)- 
tetraacetate (EGTA) whereas this does not affect other 
epitopes of LFA-1 (Y. van Kooyk, P. Weder, F. Hogervorst, 
A J. Verhoeven, A.A. le Velde, J. Borst, G.D. Keizer and
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C.G. Figdor, submitted). Ca2+ readily restores NKI-L16 
expression. Maturation/activation of PBL by in vitro cul­
ture induces the NKI-L16 epitope (Fig. 3(2)).
Expression of the NKI-L16 epitope is, however, not 
sufficient to induce cell adhesion since CTL do not aggre­
gate spontaneously7. Induction of stable cell adhesion 
requires a strong stimulatory signal (for example antigen, 
PMA and anti-CD3), which then leads to a third form of 
LFA-1 - activated LFA-1 (Fig. 3(3)).
Dispersed and locally concentrated LFA-1
it has been suggested32 that stable intercellular inter­
actions require the presence of local areas of highly 
concentrated adhesion receptors on the cell surface. Mul­
tiple receptor-ligand interactions formed in such areas 
would facilitate stable cell adhesion. Along these lines, we 
hypothesize that resting NKI-L16-negative lymphocytes 
lack areas of concentrated LFA-1 and therefore cannot 
adhere efficiently. It is possible that expression of the NKI- 
L16 epitope is in some way associated with the formation 
of clusters of LFA-1 (Fig. 3). The observation (Y. van 
Kooyk, P. Weder, F. Hogervorst, A.J. Verhoeven, A.A. le 
Veide, J. Borst, G.D. Keizer and C.G. Figdor, submitted) 
that expression of the NKI-L16 epitope is Ca2+~dependent 
suggests that Ca2+ is involved in the formation and stabil­
ization of clustered LFA-1. Preliminary light- and electron- 
microscope studies indicate different distribution patterns 
of LFA-1 on resting PBL compared to cloned CTL or NK 
cells.
Regulation of LFA-1-mediated cell adhesion at different levels
W hat is the benefit of expressing three distinct forms of 
LFA-1? As discussed above, clear advantages can be 
envisaged if LFA-1-ligand interactions can be rapidly 
switched on and off, thereby creating a mechanism to 
regulate lymphocyte adhesion and de-adhesion. But this 
does not require the existence of three forms of LFA-1. In 
our opinion, the answer to this question may be found in 
the maturation/activation state of a lymphocyte. This is 
best illustrated by the following example. One of the 
phases of an immune/inflammatory response is charac­
terized by the recruitment of leukocytes from the periph­
eral blood pool. Lymphocytes adhere to endothelial cells 
and migrate into the underlying tissues; this process is 
regulated by various adhesion pathways, including 
LFA- 1-ICAIVM interactions33. Cytokine production (IL-1, 
gamma-interferon) will locally raise the expression of 
ICAM-1 (Ref. 12) on the endothelial cells, thereby facili­
tating leukocyte adhesion in general. However, instead of 
random cell binding, it is preferable to recruit only those 
ceils that can make a positive contribution to the immune 
response. We suppose, therefore, that resting (NKI-L16- 
negative) lymphocytes are not capable of stable celi ad­
hesion, In contrast, activated or previously activated lym­
phocytes exhibiting high levels of LFA-1 and exposing 
high levels of NKI-L16 epitope can immediately bind when
LFA-1 is activated by, for instance, antigen presented by 
endothelial cells3"1, in addition, the release of cytokines 
during the immune/inflammatory response may invoke 
activation/maturation of resting cells, which thereby gain 
the NKI-L16 epitope associated with the capacity to 
rapidly adhere upon stimulation through CD2 and CD3.
Thus we propose that LFA-1-ligand interactions can be 
regulated at three levels: (1) the absolute number of 
molecules expressed at the cell surface, (2) maturation/
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Fig. 2, Role of LFA-1 in the different phases of the cytolytic response. Low-affmity interactions 
between LFA-1 and ICAM-J/2 cause initial cell contact between CTL and target cell facilita ting 
antigen recognition. Upon antigen recognition TCR-CD3-mediated signalling activates LFA-1 
possibly by phosphorylation of the (i chain resulting in high-affmity ligand binding. Subsequent 
adhesion strengthening facilitates efficient delivery of the lethal hit. Feedback mechanisms 
reversing LFA-1 by the déphosphorylation into its inactive (low-affinityj state allow the CTL to 
detach from the target cell.
activation processes which favour cell binding by pre­
viously activated NKI-L16-positive cells compared to rest- 
ng NKI-L16-negative cells and (3) specific activation of 
LFA-1 into a high affinity state.
Synopsis and discussion
The model presented here formally explains the regu­
lation of leukocyte adhesion by LFA-1. Cell-cell inter­
actions mediated by other members of the integrin *
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superfafrtily may well use similar mechanisms. PMA en­
hances jfibronectin receptor (VLA-5)-mediated cell ad­
hesion3!  and fibronectin synergyses with anti-CD3 
antibody to promote lymphocyte proliferation36, indicat­
ing that the T-cell receptor may regulate fibronectin- 
receptor-mediated adhesion. Novel findings support 
and extend this notion, showing that PMA, anti-CD2 and 
anti-CD3 antibodies can induce VLA4/VLA5- or VLA6- 
mediated lymphocyte binding to fibronectin or laminin, 
respectively37. Furthermore, two other integrins, CR3 
(CDl1b-CD18) and GPIIb-llla, express neo-epitopes 
upon activation38,39, indicating that activation can induce 
a conformational change in these molecules. Chemotac- 
tic compounds induce transient neutrophil aggregation 
and adhesion to endothelium which may be mediated 
through CR3 (Ref. 40).
Finally, an increasing body of evidence indicates that 
cell adhesion depends on dynamic membrane (integrin)- 
cytoskeletal interactions. Talin, an integral membrane 
protein, may play a major role in this process by linking 
integrin receptors to the cytoskeleton, since it co-localizes 
with several integrin molecules at cell contact areas upon 
antigen- or phorbol-ester-induced stimulation41.
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Debate in Immunology Today
Divergence of opinion is a feature of many areas of immunology. To encourage 
the exchange of opinions and ideas Immunology Today will introduce a Debate 
section later in the year. This will take the form of two rostrum-style articles 
giving alternative viewpoints on a current controversy, followed by a short 
comment by each author on the other paper.
If you have a suggestion for a topic for debate please contact the editor.
